Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients

Transplantation

Volumn 78, Issue 11, 2004, Pages 1689-1692

  Ahmed, Junaid ^a   Velarde, Claudia ^a   Ramos, Marco ^a   Ismail, Khaled ^a   Serpa, Jose ^a   Ortigosa Goggins, Mariella ^a   Parasuraman, Ravi ^a   Venkat, K K ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Cytomegalovirus; Ganciclovir prophylaxis; Kidney transplantation

Indexed keywords

GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3; TACROLIMUS;

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HLA-DR ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 10644297003     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000141364.85454.37     Document Type: Article

References (14)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338(24): 1741.
2. Patel R, Syndham DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
3. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7): S754.
4. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 1.
5. Brennan DC, Burton KG, Singer GG, et al. Prophylactic oral gancyclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843.
6. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive gancyclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123(1): 18.
7. Scnitzler MA, Lowell JA, Hmeil SP, et al. Cytomegalovirus disease after prophylaxis with oral gancyclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003; 14: 780.
8. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, et al. Long-term oral gancyclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 1174.
9. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, gancyclovir, and pencyclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42(2): 216.
10. Becker B, Becker YT, Leverson GE, et al. Reassessing the impact of Cytomegalovirus Infection in Kidney and Kidney-Pancreas Transplantation. Am J Kidney Dis 2002; 39: 1088.
11. Becker BN. Mycophenolate mofetil. Transplant Proc 1999; 31: 2777.
12. Drew WL, Miner RC, Bush DF, et al. Prevalence of resistance in patients receiving gancyclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716.
13. Limaye AP, Corey L, Koelle DM, et al. Emergence of gancyclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
14. Boivin G, Erice A, Crane DD, et al. Gancyclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after prophylaxis. J Infect Dis 1993; 168: 332.